The Venture Codex

Participated · Series D · Jul 2026

AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.